|Day Low/High||23.72 / 24.00|
|52 Wk Low/High||20.32 / 25.72|
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
Aims to empower patients with inflammatory bowel disease through unique, Marvel Custom Solutions-illustrated stories featuring a Super Hero with IBD
Deal Provides Takeda Global Rights to Selective 5-HT4 Agonist; Highlights Takeda's Commitment to Gastroenterology as a Core Therapeutic Area
Eight abstract presentations include new analyses from the EXAMINE trial and real-world databases
- Myovant to conduct global phase 3 programs of relugolix, a potential best-in-class GnRH antagonist for the treatment of uterine fibroids, endometriosis and prostate cancer
Stocks inch higher by mid-afternoon Friday as Federal Reserve Chair Janet Yellen suggest the central bank could implement another rate hike this summer.
Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.
Moves to Strengthen Portfolio Focus, Transfer Rights for CONTRAVE® and Invest in Recent Launches in United States
Acquisition provides Orexigen ownership of CONTRAVE in nearly all major global markets
New melt in your mouth tablet for appropriate adult patients with heartburn associated with Gastroesophageal Reflux Disease (GERD)
Takeda Pharmaceutical Company Limited ( TSE: 4502) today announced that the U.
New Campaign Developed to Inspire Obese and Overweight Women to Take Action and Talk with Their Doctor
Company Has Donated More Than $500,000 to Local Charities Since Program Began
Partnership Reaffirms Commitment to the Success of CONTRAVE® (naltrexone HCl / bupropion HCl extended-release tablets)
Second Study Indicates No Increased Risk of Bladder Cancer in Patients Treated With Pioglitazone, Further Reinforcing the Positive Benefit/Risk Profile
Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.
Shares of Takeda Pharmaceutical (TKPYY) are down as the company said it would fight $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging the drugmaker concealed cancer risks associated with its Actos diabetes drug,
Shares of Eli Lilly (LLY) may fall today after a jury ordered the company to pay $3 billion and Takeda (TKPYY) to pay $6 billion in punitive damages over allegations that they hid the cancer risks associated with the diabetes therapy Actos.